STADA CIS

Aktivs

The Russian holding STADA CIS is engaged in the development, production and sale of drugs in the CIS and Baltic countries, is part of the international STADA Group.

The parent company of the holding for 2010 is Nizhfarm, whose tasks include planning, consolidation of reporting, as well as analyzing the activities of the holding companies:

• NIZHFARM (Nizhny Novgorod) - global competence center for soft forms,
• MAKIZ-PHARMA (g Moscow.),
• SKOPINFARM (Ryazan region) - production of products;
• STADA Marketing,
• STADA Ukraine,
• STADA Central Asia,
• STADA Azerbaidjan,
• STADA Armenia - marketing, sale and distribution of products; * STADA PharmDevelopment - R&D division.

In 2022, Hemopharm (STADA CIS) in Obninsk is also mentioned among the assets with a focus on the production of solid dosage forms.

History

2023: Exit from Nizhfarm JSC

According to the Chekko portal, from November 1, 2023, Stada CIS withdrew from the ownership of Nizhfarm JSC.

2022: Oksana Pozdnyakova - the new head of the Russian office of Stada

On August 19, 2022, Stada announced the appointment of Oksana Pozdnyakova as head of the company's Russian office. Prior to that, she headed the division of consumer products (Consumer Healthcare) in the representative office. Read more here.

2021: Russia accounted for 15% of STADA's total turnover

At the end of 2021, STADA in Russia, the company showed significant growth: the region accounted for about 15% of STADA's total turnover in 2021. STADA in Russia demonstrated significant growth both in the Consumer HealthCare segment and in the prescription drug segment.

STADA in Russia has one of the deepest localization levels among international pharmaceutical companies - more than 65%.

2021: Appointment of Alexander Samorodov as IT Director

From February 1, 2021, Alexander Samorodov took the position of Director of Information Technology at Stada in Russia and the CIS. Alexander came to Stada from Alcon, a manufacturer of drugs and medical devices, where he served as head of the IT department in Russia. This was announced on February 1, 2021 to TAdviser by Stada. Read more here.

2020

Blocking the supply of 1.5 million products due to a labeling system failure

On November 25, 2020, it became known that Russian customs blocked the supply of 1.5 million Stada products due to a system failure. markings

If you enter into civil circulation products and data from the FGIS MDLP [federal state system for monitoring the movement of drugs - approx. Zdrav.expert] did not fully enter the AIS Roszdravnadzor, then this also blocks the further movement of drugs, despite the Government Decree No. 1779 on the notification mode, - said the head of the direction of monitoring the movement of finished products Stada Artem Selyansky.

Customs blocked deliveries of 1.5m Stada products due to labelling system failure

On November 24, 2020, Deputy Prime Minister Tatyana Golikova, speaking at a meeting of the coordinating council of human rights commissioners, noted that when the rush demand began in pharmacies, the planned work on the labeling of medicines became impossible due to a system failure. After that, the Government of the Russian Federation decided to switch to the labeling of medicines in a notification manner.

According to the information that we currently have from the constituent entities of the Russian Federation, this topic as a possible restriction on the presence of drugs in pharmacies is practically removed, "she said on November 24.

Stada asks to extend the notification regime until the transition to the transfer of data to the system on a voluntary basis, leaving the requirements for labeling and the transfer of information about the disposal of labeled drugs mandatory. The company proposed to establish an exchange of data between the information system of the Federal Customs Service and the FGIS MDLP, as well as between the AIS Roszdravnadzor and the FGIS MDLP. Then importers in Russia would not have to transfer additional information to the FSIS on the results of customs clearance, and to local manufacturers and importers on the introduction of products into civilian circulation.

Artem Selyansky recalled the rules of fair competition between Russian and foreign manufacturers. Domestic manufacturers and importers are required to transfer significantly more voluminous data than foreign ones, he explained.^[1]

Investment plan €13 million in increasing the capacity of Russian pharmaceutical enterprises

In September 2020, it was announced that Stada plans to invest €13 million over three years in increasing the capacity of Russian pharmaceutical enterprises.

"Over the past 15 years, the total amount of private investment of the company amounted to almost €1 billion. Stada sees great potential in Russian production and seeks to make the most of it. The company has one of the deepest levels of localization - more than 70% and continues to invest in this area. "

Stada notes that direct investments of international pharmaceutical companies in Russia for the period 2010-2019. amounted to about 241 billion rubles, the total contribution (taking into account labor costs and the total indirect impact on the development of the Russian economy) of international pharmaceutical companies to the Russian economy over the past 10 years exceeds 1.2 trillion rubles.

Appointment of Arminas Matsevicius as head of Stada CIS

On July 13, 2020, Stada appointed a new head for the CIS countries. It was Arminas Matsevicius, who previously held a similar position in Takeda, heading the cluster of Central Asia and the Caucasus. Read more here.

Notes